<- Go Home
Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Market Cap
$1.9B
Volume
190.5K
Cash and Equivalents
$49.6M
EBITDA
-$94.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$77.20
52 Week Low
$10.11
Dividend
N/A
Price / Book Value
10.22
Price / Earnings
-16.91
Price / Tangible Book Value
10.22
Enterprise Value
$1.7B
Enterprise Value / EBITDA
-18.35
Operating Income
-$94.8M
Return on Equity
62.28%
Return on Assets
-37.79
Cash and Short Term Investments
$198.5M
Debt
N/A
Equity
$183.8M
Revenue
N/A
Unlevered FCF
-$41.3M
Sector
Biotechnology
Category
N/A